Researchers Create New Cellular Therapy for Acute Myeloid Leukemia
Key Highlights
- The therapy targets the CG1 peptide, which is abundant on AML cells but absent on normal blood cells.
- Engineered CAR T-cells recognize the CG1/HLA-A*02:01 complex, enabling precise targeting of leukemia cells.
- Preclinical tests showed effective killing of AML cells in both lab and mouse models.
- The approach minimizes damage to healthy blood cells, reducing potential side effects.
- This development represents a significant step toward more targeted and safer AML treatments.



